Future Neurology Plain Language Summary (PLS) “Low Sodium Oxybate Improved Symptoms in Adults with Narcolepsy with Cataplexy”
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in 2024
